Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LaunchPAD-RA
PACTR202606808135933Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD1163 in rheumatoid arthritis (RA) (4 arms), sponsored by AstraZeneca. Primary endpoint: Primary efficacy endpoint. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
AZD1163
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on PACTR202606808135933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606808135933.